Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMI/REL in Pediatric Gram-negative Bacterial Infections
NCT03969901Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of imipenem + cilastatin + relebactam in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), Intra-abdominal infection (IAI), complicated urinary tract infection (cUTI), Bacteremia, sponsored by Merck & Co.. Started Oct 2019; status: completed.
02
Drugs
imipenem + cilastatin + relebactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)complicated urinary tract infection (cUTI)Bacteremia
Beyond the preview
Go deeper on NCT03969901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969901.